Current treatment for localized anal carcinoma

Current Opinion in Oncology

Volumn 19, Issue 4, 2007, Pages 396-400

  Das, Prajnan ^a   Crane, Christopher H ^a   Ajani, Jaffer A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Anal cancer; Chemoradiation; Cisplatin; Intensity modulated radiation therapy

Indexed keywords

CISPLATIN; FLUOROURACIL; MITOMYCIN C;

ADD ON THERAPY; ADJUVANT THERAPY; ADVERSE OUTCOME; ANUS CARCINOMA; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL STUDY; CLINICAL TRIAL; CONTINUOUS INFUSION; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERABILITY; FEASIBILITY STUDY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RADIATION DOSE; REVIEW; SQUAMOUS CELL CARCINOMA; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; ANUS NEOPLASMS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; FLUOROURACIL; HUMANS; MITOMYCIN; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY, INTENSITY-MODULATED;

EID: 34250016499     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32816f76de     Document Type: Review

References (21)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56:106-130.
2. Haddock MG, Martenson JA. Anal carcinoma. In: Gunderson LL, Tepper JE, editors. Clinical Radiation Oncology, 1st ed. Philadelphia, PA: Churchill Livingstone; 2000. pp. 747-761.
3. Daling JR, Weiss NS, Klopfenstein LL, et al. Correlates of homosexual behavior and the incidence of anal cancer. JAMA 1982; 247:1988-1990.
4. Melbye M, Cote TR, Kessler L, et al. High incidence of anal cancer among AIDS patients. The AIDS/Cancer Working Group. Lancet 1994; 343:636-639.
5. Penn I. Cancers of the anogenital region in renal transplant recipients: analysis of 65 cases. Cancer 1986; 58:611-616.
6. Nigro ND, Seydel HG, Considine B, et al. Combined preoperative radiation and chemotherapy for squamous cell carcinoma of the anal canal. Cancer 1983; 51:1826-1829.
7. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. Lancet 1996; 348:1049-1054.
8. Bartelink H, Roelofsen F, Eschwege F, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol 1997; 15:2040-2049.
9. Flam M, John M, Pajak TF, et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol 1996; 14:2527-2539.
10. Ajani JA, Winter KA, Gunderson LL, et al. Intergroup RTOG 98-11: a phase III randomized study of 5-fluoruracil (5-FU), mitomycin, and radiotherapy versus 5-fluorouracil, cisplatin and radiotherapy in carcinoma of the anal canal. J Clin Oncol 2006; 24:180s.
11. Gunderson LL, Winter KA, Ajani JA, et al. Intergroup RTOG 9811 phase III comparison of chemoradiation with 5-FU and mitomycin vs 5-FU and cisplatin for anal canal carcinoma: impact on disease-free, overall and colostomy-free survival [abstract]. Int J Radiat Oncol Biol Phys 2006; 66:S24.
12. Hung A, Crane C, Delclos M, et al. Cisplatin-based combined modality therapy for anal carcinoma: a wider therapeutic index. Cancer 2003; 97:1195-1202.
13. James R, Meadows H, Wan S. ACT II: the second UK phase III anal cancer trial. Clin Oncol (R Coll Radiol) 2005; 17:364-366.
14. Crehange G, Bosset M, Lorchel F, et al. Combining cisplatin and mitomycin with radiotherapy in anal carcinoma. Dis Colon Rectum 2007; 50:43-49. This paper reports an EORTC phase II trial on radiotherapy with concurrent cisplatin and mitomycin.
15. Cotter SE, Grigsby PW, Siegel BA, et al. FDG-PET/CT in the evaluation of anal carcinoma. Int J Radiat Oncol Biol Phys 2006; 65:720-725.
16. Baxter NN, Habermann EB, Tepper JE, et al. Risk of pelvic fractures in older women following pelvic irradiation. JAMA 2005; 294:2587-2593.
17. Chen YJ, Liu A, Tsai PT, et al. Organ sparing by conformal avoidance intensity-modulated radiation therapy for anal cancer: dosimetric evaluation of coverage of pelvis and inguinal/femoral nodes. Int J Radiat Oncol Biol Phys 2005; 63:274-281.
18. Milano MT, Jani AB, Farrey KJ, et al. Intensity-modulated radiation therapy (IMRT) in the treatment of anal cancer: toxicity and clinical outcome. Int J Radiat Oncol Biol Phys 2005; 63:354-361.
19. Salama JK, Mell LK, Devisetty K, et al. Multicenter outcome of anal cancer patients teated with IMRT [abstract]. Int J Radiat Oncol Biol Phys 2006; 66:S273.
20. Kachnic L, Tsai HK, Willins J, et al. Dose-painted intensity modulated radiation therapy for anal cancer: dosimetric comparison and acute toxicity. Int J Radiat Oncol Biol Phys 2006; 66:S280.
21. Devisetty K, Mell LK, Salama JK, et al. Anal cancer treated with intensity modulated radiation therapy (IMRT) and concurrent chemotherapy: a dosimetric analysis of acute gastrointestinal toxicity. Int J Radiat Oncol Biol Phys 2006; 66:S287.